HIV Gene Therapy
HIV
Pre-clinicalActive
Key Facts
About Nanite
Founded in 2019 and based in Cambridge, USA, Nanite is a private, pre-clinical biotech leveraging a proprietary AI platform called SAYER to engineer polymer nanoparticles for genetic drug delivery. The platform integrates computational design, automated synthesis, and multi-modal biological screening to rapidly identify PNPs with optimal tissue targeting, expression, and safety profiles. Nanite is initially targeting genetic diseases, with disclosed work in cystic fibrosis and an HIV gene therapy project funded by the Gates Foundation, positioning itself as a potential disruptor in the gene therapy delivery space.
View full company profileTherapeutic Areas
Other HIV Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK3844766 | GSK plc | Phase 1 |
| NanoDDI | Continuity Biosciences | Pre-clinical |